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Abstract
Background—A preliminary genome-wide linkage analysis of blood pressure in the Family
Blood Pressure Program (FBPP) was reported previously. We harnessed the power and ethnic
diversity of the final pooled FBPP dataset to identify novel loci for blood pressure thereby
enhancing localization of genes containing less common variants with large effects on blood
pressure levels and hypertension.
Methods—We performed one overall and 4 race-specific meta-analyses of genome-wide blood
pressure linkage scans using data on 4,226 African American, 2,154 Asian, 4,229 Caucasian, and
2,435 Mexican American participants (total N=13,044). Variance components models were fit to
measured (raw) blood pressure levels and two types of antihypertensive medication adjusted blood
pressure phenotypes within each of 10 subgroups defined by race and network. A modified
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Fisher's method was used to combine the p-values for each linkage marker across the 10
subgroups.
Results—Five quantitative trait loci (QTLs) were detected on chromosomes 6p22.3, 8q23.1,
20q13.12, 21q21.1, and 21q21.3 based on significant linkage evidence (defined by logarithm of
odds (LOD) score ≥3) in at least one meta-analysis and LOD scores ≥1 in at least 2 subgroups
defined by network and race. The chromosome 8q23.1 locus was supported by Asian-, Caucasian-,
and Mexican-American-specific meta-analyses.
Conclusions—The new QTLs reported justify new candidate gene studies. They may help
support results from genome-wide association studies (GWAS) that fall in these QTL regions but
fail to achieve the genome-wide significance.
Keywords
hypertension; blood pressure; meta-analysis; linkage; genetics; QTL
Introduction
According to the 2005-2006 National Health and Nutrition Examination Survey, 29% of all
US adults are hypertensive with respective prevalences of 41%, 28%, and 22% among
African, Caucasian, and Hispanic American adults1. Elevated blood pressure (BP) is the
most common modifiable risk factor for cardiovascular disease. Thus, there is great interest
in identifying the underlying genetic and environmental determinants. In 1995 the National
Heart, Lung, and Blood Institute established a collaboration of 4 multicenter networks,
known as the Family Blood Pressure Program (FBPP), to investigate the genetic
determinants of inter-individual BP variation in Asians, African Americans, Mexican
Americans, and Caucasians2. The FBPP collaboration yielded statistical power and diversity
unmatched in any individual study3.
The complete FBPP resource includes 13,516 individuals with microsatellite genotype data
from two temporally distinct study phases (phases 1 and 2 were conducted from 1995-2000
and 2000-2005, respectively). We report here a linkage analysis of the complete pooled
FBPP data, which has considerably more power for detecting QTLs for BP. Indeed, this
investigation reports multiple QTLs in comparison with previous reports based on various
subsets of the interim data 4-6.
The FBPP database permits an overall meta-analysis of all 10 subgroups defined by network
and race and 4 race-specific meta-analyses (3 cohorts each of African Americans and
Caucasians, 2 cohorts of Mexican Americans, and 2 cohorts of Asians-- Japanese and
Chinese). We conducted all analyses using the observed BP as well as two types of
antihypertensive medication adjusted systolic blood pressure (SBP), diastolic blood pressure
(DBP), mean arterial pressure (MAP), and pulse pressure (PP) phenotypes to search for
novel BP QTLs. Recent GWAS studies have identified a number of common variants
associated with BP and/or hypertension. However, they mostly include individuals of
European descent and account for only a small fraction of the phenotypic variance7.
Therefore, there is a need to identify genomic regions that harbor rare variants with
relatively large effect sizes. Detecting such regions could lead to novel findings that
complement the current GWAS results.
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Methods
Subjects
The FBPP pooled data derive from the 4 separate multicenter Networks: GenNet, GENOA,
HyperGEN, and SAPPHIRe 2 (Table 1). A detailed description of each cohort can be found
elsewhere2. All FBPP studies were approved by their respective institutional review
committees and all participants gave informed consent. All networks recruited families
ascertained through individuals with high or low BP. GenNet recruited African American,
Caucasian, and Mexican American nuclear families ascertained through young/middle-aged
probands with untreated high-normal BP. GENOA recruited African American and
Caucasian sibships containing at least 2 hypertensive members, Mexican American sibships
containing at least 2 adult onset diabetics and all full siblings of each index pair. HyperGEN
recruited African American and Caucasian hypertensive siblings, their parents, and 1 or
more of a sibling's untreated offspring; sibships containing one severely hypertensive
member were ascertained preferentially. SAPPHIRe recruited Chinese and Japanese sib
pairs that were highly concordant or discordant for hypertension.
Genotyping
The Mammalian Genotyping Service in Marshfield, WI, performed all genome wide scans8.
For all cohorts except GenNet Mexican Americans, we used 362 autosomal markers (with
average inter-marker distance 9.5 cM) after removing those with high (>70%) missing rates,
that were duplicates of the same position, or were mapped to multiple locations in the
genome. GenNet Mexican Americans were genotyped much later, using a subsequent
(marker) screening set. After quality control, this yielded 372 Marshfield autosomal markers
(with average inter-marker distance 9.4 cM). Most (71%) of the GenNet Mexican American
markers overlapped or shared a genetic distance with markers used in other cohorts. Family
relationships were verified using graphical representation of relationships (GRR) and
affected sibpair exclusion mapping (ASPEX), while Mendelian errors were removed via
MapMaker/SIBS and Pedcheck4.
Phenotype Adjustment
All networks used a consistent BP measurement protocol4, 6. The pooled FBPP dataset
includes the average of three sitting SBP or DBP measurements taken using Dinamap (for
504 GenNet African Americans and 2 GenNet Caucasians, the measurements were taken
using the Omron). MAP was estimated by the sum of two-thirds the average DBP and one-
third the average SBP. PP was computed as the difference between the average SBP and
DBP. We excluded the BP phenotypes of participants with hypertension diagnosed after age
60 or with BMI, SBP, DBP, MAP, or PP values 4 or more standard deviations from the
mean of the subgroup (based on network, race, and sex).
The observed blood pressures (SBP, DBP, MAP, PP) of all individuals, irrespective of
antihypertensive medication use, composed the “raw” set of phenotypes. Next, we assumed
the measured BP of individuals treated with antihypertensive medications was lower on
average than if the individuals had not been treated. Since any attempt to adjust BP for
medication use is only an approximation, we calculated two different sets of “medication
adjusted” BP phenotypes. The “+10/5” medication adjusted values9 were derived by adding
10mmHg to SBP and 5mmHg to DBP (only for those known to be taking medications).
Similarly, the “+15/10” medication adjusted values10 were obtained by adding 15mmHg to
SBP and 10 mmHg to DBP. The medication adjusted PP and MAP were calculated from the
medication adjusted SBP and DBP values. The observed BP phenotypes were used for those
untreated or with unknown medication status. Only one medication adjustment was
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performed for PP since both “+10/5” and “+15/10” result in the same values for all
individuals (obtained by adding 5 mmHg to PP for medication users).
We narrowed our search to primarily hypertension genes instead of genes primary for a
comorbidity (such as BMI) and secondary to hypertension. Therefore, phenotypes were also
adjusted for BMI in addition to age, age-squared, age-cubed, and field center within each
subgroup (defined by network, race, and sex), retaining terms significant at 5%. The residual
phenotypes were standardized to a mean of 0 and standard deviation of 1. We excluded any
covariate adjusted phenotype value that is 4 or more standard deviations away from the
mean of the subgroup (fewer than 3 values were excluded for any phenotype in any group).
Statistical Analysis
Genome-wide linkage analyses were carried out within subgroups defined by network and
race (after male and female blood pressure residuals were combined) using the multipoint
variance components method as implemented in Merlin11. We used sex-averaged genetic
distances from the Marshfield map and allele frequencies estimated from our samples. We
tested all markers for additive genetic variance due to a quantitative trait locus (QTL). For
GenNet Mexican American participants, we completed the linkage analysis at the locations
of the 372 genotyped markers plus the 90 markers exclusive to the 9 other network-race
subgroups. Overall and race-specific meta-analyses were conducted by combining p-values
of the 362 common markers using a modification of Fisher's method12.
Definition of a Quantitative Trait Locus (QTL)—We define a QTL as a genomic
segment yielding a significant LOD score (≥3) in any meta-analysis in addition to suggestive
evidence (with a LOD score ≥1) in at least 2 subgroups defined by network and race for any
blood pressure phenotype.
Results
After excluding singletons, our analysis sample (N=13,044) included 2,154 Asians, 4,226
African Americans, 2,435 Mexican Americans, and 4,229 Caucasians. Table 1 displays the
summary statistics for each network stratified by race and sex after removal of BP outliers,
BMI outliers, and those with hypertension diagnosis after age 60.
Multipoint variance components LOD scores are shown in Table 2. Loci are included if they
yielded LOD scores ≥3 (in bold) for any phenotype in any analysis (the overall meta-
analysis, race-specific meta-analysis, or network-race specific analysis). Six of the nine
distinct loci presented in Table 2 are significantly linked to pulse pressure. Five of the 9 loci
met our (stringent) definition of a QTL: one QTL from each of the overall, African-
American, and Hispanic meta-analyses, and two from the Caucasian meta-analysis (see the
online supplement for heritabilities at QTLs). All Asian meta- and cohort-specific linkage
analyses yielded maximum LOD scores ≤ 2.57. Thus, this ethnic group is represented in
Table 2 only through its contribution to the overall meta-analysis.
Table 3 shows the network-race subgroups contributing evidence to each of the 5 QTLs. Of
the five loci with meta-analysis LOD scores ≥3, the chromosome 8q23.1 (119.22 cM) locus
had two or more race-specific meta-analysis LOD scores ≥1. Figure 1 displays the overall
and race-specific meta-analysis linkage evidence between raw DBP and chromosome 8
(positions 77-165 cM). This overall meta-analysis QTL was supported by Asians,
Caucasians, and Mexican Americans. African Americans failed to show any corroborating
evidence at this locus.
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The African-American meta-analysis QTL on chromosome 6p22.3 (42.27 cM) was
substantiated by GenNet and HyperGEN African Americans while the Caucasian meta-
analysis QTL on chromosome 21q21.1(13.05 cM) was supported by all 3 Caucasian studies.
The fourth QTL on chromosome 21q21.3 (24.73 cM) was supported by all three Caucasians
cohorts and HyperGEN African Americans. The Hispanic meta-analysis locus at 20q13.12
(62.32 cM) achieved significant linkage in GENOA Mexican Americans and had a LOD
score ≥1 for GenNet Caucasians. Figure 2 displays the race-specific meta-analysis results for
the phenotypes with the highest LOD scores at their respective linkage peaks on
chromosomes 6, 20, and 21.
The remaining 4 loci on chromosome 1q31.3 (212.44 cM), 11q23.1 (105.74 cM), 17q24.2
(89.32 cM), and 20q13.32 (95.70 cM) presented in Table 2 had significant cohort-specific
LOD scores but none achieved a significant meta-analysis LOD score. All QTLs except
17q24.2 had LOD scores ≥1 in at least one additional subgroup defined by network and race
(see online supplement). Finally, we identified a total of 47 secondary QTLs, each one
supported by a LOD score ≥ 2 in any of the subgroups or meta-analyses (see the online
supplement). All QTLs were located on 17 of the 22 autosomes.
Discussion
These are both exciting and challenging times to undertake genetic dissection of common
complex diseases and disease related traits. They are exciting because the number of
promising tools available is constantly on the increase and challenging because the current
GWAS findings for BP explain a very small fraction of the total heritability. For example,
recent meta-analyses from two large consortia (Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) and Global Blood Pressure Genetics Consortium
(GBPGEN)) identified 13 loci through GWAS that collectively explain less than 2 % of SBP
and DBP variances13-14. There is growing consensus that this is largely because of our
reliance on “common variants” to explain the genetic heritability of common phenotypes.
Finding the missing heritability is the formidable challenge we face7. While linkage analysis
generally failed to advance the field of common complex traits, we believe that it has a
unique role to play in the current debate. In the past, QTLs identified through linkage
analysis have been followed up through common variants at positional candidate genes. It is
more likely that QTLs are localizing genes with relatively low frequency variants having
considerably larger effect sizes. Candidate gene-based resequencing suggests that less
common genetic variants contribute to the phenotypic variance of common diseases15. Seen
in this light, we believe that the QTLs reported here for BP make an important contribution.
By harnessing the large sample size of the complete FBPP database, we were able to
identify 5 strong QTLs for BP. The most promising QTL for DBP on chromosome 8q23.1
(119.22cM, marker=D8S1132, LOD=3.12) was identified by the overall meta-analysis of all
10 subgroups defined by network and race. The main finding in Asians, especially given the
limited sample size of the SAPPHIRe Japanese cohort (N=588), was their support for this
QTL. Both SAPPHIRe Chinese (LOD=1.52) and SAPPHIRe Japanese (LOD=1.11) are
major contributors to linkage at D8S1132. The maximum LOD score of any Asian meta-
analysis across all phenotypes and markers was 2.57 for DBP on chromosome 8q22.2 at
110.2 cM (8.14 Mbps from the overall meta-analysis peak). The same genomic segment
(8q22-23) was previously linked to essential hypertension in 173 affected individuals in a
2,180-member pedigree in Campora, Italy16. Significant association between SBP and
marker D8S592 on chromosome 8q24.11 (125.3 cM) was reported earlier in GENOA
Caucasians17. While we lacked significant evidence for this QTL in African Americans, a
genome-wide association study (GWAS) of 1,017 normotensive African Americans
identified a significant (p=1.59×10−8) association between SBP and rs17365948 on
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chromosome 8q22.3 (5 Mb from our marker D8S1132)18. This result was not supported in
the GWAS replication sample of 980 West Africans (p=0.507). A disparity in minor allele
frequencies (MAF) between the African American (MAF=0.113) and West African
(MAF=0.005) samples could be responsible in part for the discrepancy in results18.
Moderate evidence for linkage (LOD=1.74) was found between D8S1132 and the log-
transformed DBP in subjects from rural Nigeria19. The significant SNP (rs17365948) is in
the intron of YWHAZ, which may have a role in regulating insulin sensitivity
(http://genome.ucsc.edu)20. Other candidate genes in this region include ANGPT1, ZFPM2,
and OXR1. Angiopoietin, encoded by ANGPT-1, induces pulmonary hypertension in
rodents, is increased in humans suffering from essential hypertension which decreases after
successful antihypertensive treatment16, 21. ZFPM2 codes a zinc finger protein that may
modulate the activity of the GATA proteins that help regulate mammalian hematopoiesis
and cardiogenesis20. Oxidation resistance 1 (OXR1), the closest gene, may help prevent
oxidative damage20.
The QTL for PP on chromosome 6p22.3 (42.27 cM, marker=D6S2439, LOD=3.76) from the
African American-specific meta-analysis has also been implicated for SBP in a GWAS of
normotensive African Americans18. The significant (p=3.42×10−9) association between SBP
and rs16877320 on chromosome 6p22.3 (8 Mb from our marker D6S2439) failed to
replicate in 980 West Africans (p=0.781)18. Again a discrepancy in MAF could be
responsible in part. The MAF of the SNP in the African American and West African
samples were 0.132 and 0.023, respectively18. Linkage studies have provided evidence for
this locus with other BP phenotypes in other ethnicities. Postural changes in SBP
(LOD=1.9) and DBP (LOD =1.7) were both linked, at least tentatively, to D6S2439 in 498
HyperGEN Caucasian hypertensive sibpairs22. Potential or significant linkage of SBP within
10 cM of D6S2439 has been demonstrated in western Europeans (52 cM, LOD=1.97)23 and
GENOA Hispanics (34.2 cM, p=0.002)17. Early studies hinted that a genomic segment near
HLA class II was linked to essential hypertension24. D6S2439 is approximately 5.6 Mbps
from HLA-A and 8.2 Mbps from HLA-DRB1. D6S2439 is also 7.2 Mbps from the tumor
necrosis factor-alpha gene (TNF) which was associated with obesity-related hypertension in
non-morbidly obese French-Canadians25. Tumor necrosis factor amplifies the production of
angiotensinogen and endothelin-1 25; the latter is a potent vasoactive peptide24.
The two QTLs at 21q21.1 (13.05cM, marker=D21S1437) for PP (LOD=4.55) and SBP
(LOD=3.17) and 21q21.3 (24.73 cM, marker=D21S2052) for PP (LOD=3.60) and SBP
(LOD=3.01) may implicate one or more BP associated genes. The confidence interval for PP
subsumes that for SBP, although different genetic causes may be contributing to SBP and
PP. The number of peaks encompassing these two neighboring markers is indeterminate but
sufficient supporting evidence is found in the intervening genomic region. A previous
analysis of log-transformed pulse pressure in the FBPP phase 1 pooled data identified a
significant locus in Caucasians (LOD=4.3) at 18 cM and combined African Americans and
Caucasians (LOD=3.2) at 19 cM 4. The same analysis yielded suggestive linkage in all racial
groups combined (LOD=2.1) at 21 cM and GENOA Caucasians (LOD=2.2) at 17 cM 4. A
suggestive linkage (LOD=2.44) between 21q21 and MAP was established in Mexican
Americans from the San Antonio Family Heart Study26. A significant association between
SBP and D21S2052 at 24.73 cM was previously reported in GENOA Mexican Americans17.
A promising region for DBP in proximity to 24.73 cM was also discovered during a
secondary analysis of low concordant sibpairs from Anqing, China27. Admixture mapping
methods have indicated that 21q21 may contain genes influencing risk of hypertension in
African Americans28-29. In the admixture mapping analysis of Dallas Heart Study sample
using 1,890 ancestry informative SNPs, the 1-unit Z score drop region spans from
8-30cM 29, which is consistent with the region identified in this study. A GWAS of
normotensive African Americans identified a suggestive (p=5.73×10−6) association between
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DBP and rs2823756 on chromosome 21q21.1 (4 Mb from our marker D21S1437)18. Perhaps
clues about potential candidate genes can be gleaned from the suggestive bivariate linkage
evidence (LOD=3.03) of D21S1437 on chromosome 21q21.1 (13.05 cM) with C-reactive
protein (CRP) and fibrinogen in GENOA Caucasians30. Both CRP and fibrinogen are
inflammation indicators and predictors of cardiovascular disease31-32. CRP inhibits
endothelial nitric oxide synthase expression, while fibrinogen helps determine plasma
viscosity30 and is a member of the coagulation cascade.
Our fifth QTL for PP on chromosome 20q13.12 (62.32 cM, marker=D20S481, LOD=4.40)
was discovered due to the inclusion of Mexican American participants. This QTL was
linked previously to pulse pressure in GENOA Hispanics (LOD=4.4) 4 and the slope and
curvature of repeated measures of SBP over multiple visits in the Framingham Heart
Study33. Suggestive linkage for SBP variation was discovered near this locus in GENOA
Caucasian discordant sibpairs34. A tentative linkage (LOD=1.75) between SBP and
chromosome 20q13 was observed in a sample from the isolated Croatian island Vis35. A
single nucleotide polymorphism, located 4.2 Mbps from D20S481, was associated with SBP
in both the Vis population and the British 1958 Birth Cohort. Barbalic et al. argue that the
potassium voltage gate channel gene (KCNB1) and the prostaglandin I2 (prostacyclin)
synthase gene (PTGIS) are candidates for the association35. KCNB1 belongs to the voltage-
gated potassium channel family that is involved in insulin secretion, heart rate regulation,
neurotransmitter release, and more. PTGIS, 4.35 Mbps from our D20S481, helps catalyze
prostaglandin H2 to the vasodilator platelet aggregation inhibitor prostacyclin35. Japanese
participants of the Suita Study with particular genotypes in the promoter region of the
human prostacyclin synthase gene had significantly higher SBP, PP, and odds of
hypertension36.
The variable effect of antihypertensive medication adjustment on linkage evidence can be
seen in Table 2. The +15/10 and +10/5 adjustments correspond to both increased (e.g., +15
SBP in the Caucausian meta-analysis of chromosome 21 position 24.73 cM) and decreased
(e.g., +10 DBP in the overall meta-analysis of chromosome 8 position 119.22) LOD scores.
This fluctuation in BP linkage evidence by medication adjustment scheme has been well-
documented9-10, 37. The analysis of raw (measured) BP values obscures the contribution of
treated individuals to the familial component of BP9. We used medication adjustment to
infer the underlying pre-treatment BP value10. The BP values of treated individuals were
augmented by a constant value to combat negative bias and the resultant loss of power 10.
This adjustment method works well in a variety of settings10 but is an approximation that
may over- or underestimate the underlying BP and therefore the exact effect on the LOD
score is difficult to predict. Thus, we present the linkage evidence from the raw and
medication adjusted analyses hoping that they will bracket the correct results.
Characteristics of hypertension such as prevalence, age of diagnosis, and severity differ
among ethnic groups38. The failure to replicate a significant locus across racial groups
within the same study does not necessarily suggest that the genetic effect is race-specific. A
hypertension susceptibility gene may have the same underlying biological function across
races but varying etiological variants or interacting genetic/environmental modulators may
lead to different observed effect sizes and hence the power to detect the gene within each
race39. Specifically, the allelic heterogeneity of a locus across populations may be a reason
why association results sometimes fail to replicate across studies. The 8q23.1 locus
substantiated by all non-African American FBPP cohorts, normotensive African Americans
from Washington DC, and a sample of Nigerians shows the complicated interplay between
genes and environment. Integrating these results from linkage with GWAS results to
generate testable hypotheses is a logical next step. The so-called missing heritability7 may
be found only when all hypertension susceptibility loci (both common and rare),
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environmental factors, and relevant gene-gene and gene-environment interactions are fully
identified and modeled together. Our linkage findings may advance us towards this goal by
providing supporting evidence for potential BP loci that fail to meet genome-wide
significance in current GWAS studies due to small effect sizes. Results reported in this study
can be used to derive weighting schemes for interpreting results from GWAS7. We conclude
that low frequency variants in genes localized in the QTLs may contribute to the missing
heritability of hypertension.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Overall and race-specific meta-analysis results for DBP on chromosome 8.
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Figure 2.
The race-specific meta-analysis linkage evidence for chromosomes 6, 20, and 21. A) The
African American meta-analysis linkage evidence between pulse pressure and chromosome
6. B) The Mexican American meta-analysis linkage evidence between pulse pressure and
chromosome 20. C) The Caucasian meta-analysis linkage evidence between medication
adjusted pulse pressure and chromosome 21, as well as +15 medication adjusted SBP and
chromosome 21.
Simino et al. Page 13
Am J Hypertens. Author manuscript; available in PMC 2012 July 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Simino et al. Page 14
Ta
bl
e 
1
Ch
ar
ac
te
ris
tic
s o
f s
ub
jec
ts 
in 
lin
ka
ge
 an
aly
sis
.
N
et
w
or
k
R
ac
e
N
fa
m
Se
x
N
*
M
ea
n 
A
ge
(ye
ar
s)
H
T %
M
ed
s
%
M
ea
n 
BM
I
(k
g/m
2 )
M
ea
n 
SB
P
(m
mH
g)
M
ea
n 
D
BP
(m
mH
g)
M
ea
n 
M
A
P
(m
mH
g)
M
ea
n 
PP
(m
mH
g)
G
en
N
et
B
la
ck
26
6
F
47
5
42
38
27
32
.7
12
6.
1
76
.8
93
.2
49
.3
M
32
0
39
30
11
27
.1
12
9.
2
79
.0
95
.7
50
.2
H
isp
an
ic
18
4
F
49
2
36
11
9
29
.0
10
9.
4
60
.5
76
.8
48
.9
M
30
1
33
13
8
28
.1
11
6.
2
63
.3
80
.9
52
.9
W
hi
te
22
6
F
53
7
46
33
26
29
.2
11
9.
8
67
.7
85
.1
52
.2
M
43
4
44
34
23
28
.9
12
7.
1
72
.7
90
.8
54
.4
To
ta
l
67
6
-
2,
55
9
41
27
18
29
.4
12
1.
0
69
.7
86
.8
51
.2
G
EN
O
A
B
la
ck
51
8
F
1,
15
5
57
73
64
32
.0
13
0.
3
69
.1
89
.5
61
.2
M
52
1
59
68
54
28
.3
13
1.
1
73
.9
92
.9
57
.2
H
isp
an
ic
39
2
F
96
9
55
50
39
31
.5
12
6.
9
68
.3
87
.9
58
.6
M
67
3
55
48
29
29
.6
12
9.
6
74
.4
92
.8
55
.2
W
hi
te
47
8
F
76
8
55
73
67
30
.3
13
0.
8
72
.8
92
.2
58
.0
M
64
0
56
78
64
30
.3
13
5.
6
79
.9
98
.4
55
.7
To
ta
l
1,
38
8
-
4,
72
6
56
65
54
30
.6
13
0.
4
72
.3
91
.6
58
.2
H
yp
er
G
EN
B
la
ck
52
2
F
1,
15
9
47
71
67
33
.5
12
8.
7
73
.1
91
.6
55
.6
M
59
6
46
65
56
29
.7
13
0.
8
77
.1
95
.0
53
.7
W
hi
te
43
0
F
96
8
54
61
59
29
.2
12
0.
3
66
.9
84
.7
53
.5
M
88
2
52
61
57
29
.0
12
2.
8
72
.5
89
.3
50
.3
To
ta
l
95
2
-
3,
60
5
50
65
60
30
.6
12
5.
4
72
.0
89
.8
53
.4
SA
PP
H
IR
e
Ch
in
es
e
40
6
F
87
1
52
60
53
24
.8
12
7.
4
73
.7
91
.6
53
.7
M
69
5
50
70
57
25
.9
13
3.
2
81
.9
99
.0
51
.4
Ja
pa
ne
se
15
8
F
34
6
59
82
77
26
.4
13
2.
7
75
.3
94
.4
57
.5
M
24
2
59
84
75
27
.4
13
6.
1
83
.6
10
1.
1
52
.4
To
ta
l
56
4
-
2,
15
4
53
69
60
25
.7
13
1.
1
77
.8
95
.6
53
.3
TO
TA
L
3,
58
0
13
,0
44
51
58
49
29
.7
12
7.
1
72
.4
90
.6
54
.7
N
O
TE
: N
fa
m
=
n
u
m
be
r o
f f
am
ili
es
; N
=s
am
pl
e 
siz
e;
 H
T%
=p
er
ce
nt
 sa
m
pl
e 
w
ho
 a
re
 h
yp
er
te
ns
iv
e;
 M
ed
s%
=p
er
ce
nt
 sa
m
pl
e 
w
ho
 a
re
 o
n 
an
tih
yp
er
te
ns
iv
e/
di
ur
et
ic
 m
ed
ic
at
io
ns
; B
M
I=
bo
dy
 m
as
s i
nd
ex
;
SB
P=
sy
sto
lic
 b
lo
od
 p
re
ss
ur
e;
 D
BP
=d
ia
sto
lic
 b
lo
od
 p
re
ss
ur
e;
 M
A
P=
m
ea
n 
ar
te
ria
l p
re
ss
ur
e;
 P
P=
pu
lse
 p
re
ss
ur
e
Am J Hypertens. Author manuscript; available in PMC 2012 July 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Simino et al. Page 15
*
Th
e 
nu
m
be
r o
f i
nd
iv
id
ua
ls 
ap
pe
ar
in
g 
in
 b
ot
h 
th
e 
ph
en
ot
yp
e 
an
d 
ge
no
ty
pe
 d
at
as
et
s. 
12
,9
95
 in
di
vi
du
al
s h
av
e s
om
e m
ic
ro
sa
te
lli
te
 d
at
a, 
11
,9
32
 h
av
e o
ne
 o
r m
or
e n
on
-o
ut
lie
r c
ov
ar
ia
te
-a
dju
ste
d b
loo
d p
res
sur
e
v
al
ue
s, 
an
d 
13
,0
31
 h
av
e 
ei
th
er
 so
m
e 
m
ic
ro
sa
te
lli
te
 o
r s
om
e 
no
n-
ou
tli
er
 c
ov
ar
ia
te
 a
dju
ste
d p
he
no
typ
e i
nfo
rm
ati
on
.
Am J Hypertens. Author manuscript; available in PMC 2012 July 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Simino et al. Page 16
Ta
bl
e 
2
G
en
om
e-
w
id
e 
sig
ni
fic
an
t l
oc
i f
ro
m
 m
et
a-
an
al
ys
is 
an
d 
co
ho
rt-
sp
ec
ifi
c 
lin
ka
ge
 a
na
ly
sis
.
SB
P
D
BP
M
A
P
PP
R
ac
e
A
na
ly
sis
C
hr
Po
s
(cM
)
R
aw
+
10 M
A
+
15 M
A
R
aw
+
5
M
A
+
10 M
A
R
aw
+
10
/5
M
A
+
15
/1
0
M
A
R
aw
M
A
A
ll
M
et
a
8
11
9.
22
1.
80
1.
92
2.
04
3.
12
2.
47
1.
61
2.
52
2.
65
2.
15
0.
43
0.
41
A
fr
ic
an
M
et
a
6
42
.2
7
0.
85
0.
91
0.
86
0.
01
0.
00
0.
02
0.
04
0.
13
0.
16
3.
76
3.
23
A
m
er
ic
an
H
yp
er
G
EN
1
21
2.
44
0.
88
1.
39
1.
55
0.
00
0.
05
0.
17
0.
17
0.
41
0.
61
2.
82
3.
16
C
au
ca
sia
n
M
et
a
21
13
.0
5
3.
12
3.
17
2.
87
0.
96
0.
76
0.
56
1.
73
1.
52
1.
24
4.
36
4.
55
G
EN
O
A
21
13
.0
5
2.
83
2.
20
1.
73
1.
24
0.
76
0.
45
2.
00
1.
41
0.
96
3.
06
2.
69
M
et
a
21
24
.7
3
2.
15
2.
86
3.
01
1.
08
0.
81
0.
57
1.
57
1.
46
1.
18
2.
93
3.
60
G
en
N
et
20
95
.7
0
2.
39
2.
58
2.
89
1.
37
1.
62
1.
98
2.
52
3.
12
3.
09
1.
03
0.
90
M
ex
ic
an
M
et
a
20
62
.3
2
1.
91
1.
75
1.
50
0.
44
0.
53
0.
46
1.
28
1.
07
0.
92
4.
40
3.
98
A
m
er
ic
an
G
EN
O
A
20
62
.3
2
2.
69
1.
81
1.
44
0.
91
0.
69
0.
54
1.
60
0.
87
0.
59
5.
43
4.
68
G
en
N
et
11
10
5.
74
1.
24
0.
88
0.
84
1.
30
2.
46
3.
09
2.
69
2.
56
2.
63
0.
37
0.
24
G
EN
O
A
17
89
.3
2
2.
42
2.
66
2.
51
0.
50
0.
50
0.
56
1.
29
1.
36
1.
27
3.
04
3.
15
N
O
TE
: R
aw
=m
ea
su
re
d 
ph
en
ot
yp
e;
 M
A
=m
ed
ic
at
io
n 
ad
jus
ted
 ph
en
oty
pe
; +
5 M
A=
Ra
w+
5 f
or 
an
tih
yp
ert
en
siv
e/d
iur
eti
c t
ak
ers
; +
10
 M
A=
Ra
w+
10
 fo
r a
nti
hy
pe
rte
nsi
ve
/di
ure
tic
 ta
ke
rs;
 +1
5 M
A=
Ra
w+
15
 fo
r
an
tih
yp
er
te
ns
iv
e/
di
ur
et
ic
 ta
ke
rs
; +
10
/5
 M
A
=p
he
no
ty
pe
 ca
lc
ul
at
ed
 fr
om
 +
10
 M
A
 S
BP
 an
d 
+5
 M
A
 D
BP
; +
15
/1
0 
M
A
=p
he
no
ty
pe
 ca
lc
ul
at
ed
 fr
om
 +
15
 M
A
 S
BP
 an
d 
+1
0 
M
A
 D
BP
. B
ot
h 
+1
0/
5 
M
A
 an
d
+
15
/1
0 
M
A
 re
su
lt 
in
 th
e s
am
e P
P 
va
lu
es
 an
d 
LO
D
 sc
or
es
. T
he
 A
sia
n 
m
et
a-
, S
A
PP
H
IR
e C
hi
ne
se
 co
ho
rt-
sp
ec
ifi
c, 
or
 S
A
PP
H
IR
e J
ap
an
es
e c
oh
or
t-s
pe
ci
fic
 an
al
ys
es
 d
id
 n
ot
 y
ie
ld
 an
y 
LO
D
 sc
or
es
 ≥
 3
.
Am J Hypertens. Author manuscript; available in PMC 2012 July 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Simino et al. Page 17
Ta
bl
e 
3
Co
ho
rt 
sp
ec
ifi
c 
lin
ka
ge
 re
su
lts
 (L
OD
 sc
ore
s ≥
1) 
for
 th
e f
ive
 bl
oo
d p
res
su
re 
QT
Ls
.
M
et
a
C
hr
Po
sit
io
n
C
oh
or
t
Ph
en
ot
yp
es
*
 
w
ith
 L
O
D
 sc
or
e ≥
1
M
ax
im
um
 L
O
D
 sc
or
e
V
al
ue
Ph
en
ot
yp
e†
O
ve
ra
ll
8
11
9.
22
G
en
N
et
 C
au
ca
sia
ns
SB
P,
 D
BP
, M
A
P
1.
84
+
5 
D
BP
G
en
N
et
 M
ex
ic
an
 A
m
er
ic
an
s
SB
P
1.
64
+
10
 S
BP
G
EN
O
A
 M
ex
ic
an
 A
m
er
ic
an
s
M
A
P
1.
77
R
aw
 M
A
P
SA
PP
H
IR
e 
Ch
in
es
e
D
B
P,
 M
A
P
1.
52
R
aw
 D
B
P
SA
PP
H
IR
e 
Ja
pa
ne
se
D
B
P
1.
11
R
aw
 D
B
P
A
fr
ic
an
 A
m
er
ic
an
6
42
.2
7
G
en
N
et
 A
fri
ca
n 
A
m
er
ic
an
s
PP
2.
25
R
aw
 P
P
H
yp
er
G
EN
 A
fri
ca
n 
A
m
er
ic
an
s
PP
1.
64
R
aw
 P
P
C
au
ca
sia
n
21
13
.0
5
G
en
N
et
 C
au
ca
sia
ns
SB
P,
 P
P
1.
54
+
15
 S
BP
G
EN
O
A
 C
au
ca
sia
ns
SB
P,
 D
BP
, M
A
P,
 P
P
3.
06
R
aw
 P
P
H
yp
er
G
EN
 C
au
ca
sia
ns
PP
1.
17
M
A
 P
P
C
au
ca
sia
n
21
24
.7
3
G
en
N
et
 C
au
ca
sia
ns
SB
P,
 P
P
1.
71
+
15
 S
BP
G
EN
O
A
 C
au
ca
sia
ns
SB
P,
 P
P
2.
23
M
A
 P
P
H
yp
er
G
EN
 A
fri
ca
n 
A
m
er
ic
an
s
SB
P,
 D
BP
, M
A
P
1.
60
+
10
/5
 M
A
P
H
yp
er
G
EN
 C
au
ca
sia
ns
D
B
P,
 M
A
P
1.
26
+
5 
D
BP
M
ex
ic
an
 A
m
er
ic
an
20
62
.3
2
G
en
N
et
 C
au
ca
sia
ns
SB
P
1.
52
R
aw
 S
BP
G
EN
O
A
 M
ex
ic
an
 A
m
er
ic
an
s
SB
P,
 M
A
P,
 P
P
5.
43
R
aw
 P
P
*
Fo
r t
he
 p
he
no
ty
pe
(s)
 lis
ted
, L
OD
 sc
ore
s≥
1 f
or 
an
y c
om
bin
ati
on
 of
 ra
w,
 +1
0/5
 m
ed
ica
tio
n a
dju
ste
d, 
an
d/o
r +
15
/10
 m
ed
ica
tio
n a
dju
ste
d.
† S
ee
 fo
ot
no
te
 to
 T
ab
le
 2
 fo
r p
he
no
ty
pe
 d
ef
in
iti
on
s
Am J Hypertens. Author manuscript; available in PMC 2012 July 26.
